Astaxanthin has the ability to significantly lower systolic blood pressure in rats, according to a new study performed at Georgetown University Medical Center.
Astaxanthin has the ability to significantly lower systolic blood pressure in rats, according to a new study performed at Georgetown University Medical Center. This study joins three other past studies performed at the Toyama Medical and Pharmaceutical University in Japan which researched astaxanthin’s ability to reduce hypertension as well mechanism of actions for this benefit.
In the Georgetown University study, tests suggested that the Renin-Angiotensin system was involved in the ability of astaxanthin to lower blood pressure. Also, at higher dosage levels it was shown that astaxanthin influenced circulating TNF-α and MCP-1 and lessened fat oxidation in the liver and kidneys. This is an indication that astaxanthin may help to reduce stress.
The study was sponsored by Fuji Chemical Industry (Japan) and performed using AstaREAL astaxanthin.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.
Recent review makes the case for testing omega-3 fatty acid levels in humans
May 23rd 2024The article commissioned by The Global Organization for EPA and DHA Omega-3s (GOED) reviewed the state of omega-3 fatty acid testing, highlighting the value of testing and the commercially available options for diagnostic testing.
Epax launches concentrated oil that combines omegas 3, 9, and 11
May 10th 2024The blend of long-chain polyunsaturated fatty acids and long-chain monounsaturated fatty acids combines the heart and brain health benefits of omegas-3s with the skin and metabolic health benefits of omegas 9 and 11.